US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its Emblaveo (aztreonam and avibactam). The drug is the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic approved for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI).
Emblaveo: A Breakthrough Antibiotic Combination
Emblaveo combines aztreonam, a monobactam antibiotic, with avibactam, a β-lactamase inhibitor that protects aztreonam from serine β-lactamase hydrolysis and restores its activity against bacteria that co-produce Metallo-β-lactamases (MBLs) and serine β-lactamases. This combination makes Emblaveo a powerful tool in the fight against antibiotic-resistant infections.
Global Development and Commercialization
Emblaveo is co-developed by AbbVie and Pfizer (NYSE: PFE). Pfizer holds commercialization rights to the drug globally, except in the US and Canada, where AbbVie holds the rights. The drug previously received marketing approval in the European Union (EU) in April of last year, marking a significant milestone in its global development.-Fineline Info & Tech
